# A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors

> **NCT05781386** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Simcere Biologics Co., Ltd** · enrollment: 255 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Cutaneous T Cell Lymphoma

## Interventions

- **DRUG:** SIM1811-03 or in combination with Sintilimab injectiont

## Key facts

- **NCT ID:** NCT05781386
- **Lead sponsor:** Jiangsu Simcere Biologics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-06
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05781386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05781386, "A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05781386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*